Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides.
Many nonsteroidal anti-inflammatory drugs (NSAIDs) which have antiproliferative activity in colon cancer cells are carboxylate compounds forming acyl glucuronide metabolites. Acyl glucuronides are potentially reactive, able to hydrolyse, rearrange into isomers, and covalently modify proteins under physiological conditions. This study investigated whether the acyl glucuronides (and isomers) of the carboxylate NSAIDs diflunisal, zomepirac and diclofenac had antiproliferative activity on human adenocarcinoma HT-29 cells in culture. Included as controls were the carboxylate NSAIDs themselves, the non-carboxylate NSAID piroxicam, and the carboxylate non-NSAID valproate, as well as its acyl glucuronide and isomers. The compounds were incubated at 1-3000 microM with HT-29 cells for 24 hr, with [3H]-thymidine added for an additional 2 hr incubation. IC50 values were calculated from the concentration-inhibition response curves for thymidine uptake. The four NSAIDs inhibited thymidine uptake, with IC50 values about 200-500 microM. All of the NSAID acyl glucuronides (and isomers, tested in the case of diflunisal) showed antiproliferative activity broadly comparable to the parent drugs. This activity may stem from direct uptake of intact glucuronide/isomers followed by covalent modification of proteins critical in the cell replication process. However, hydrolysis during incubation and cellular uptake of liberated parent NSAID will play a role. In HT-29 cells incubated with zomepirac, covalently modified proteins in cytosol were detected by immunoblotting with a zomepirac antibody, suggesting that HT-29 cells do have the capacity to glucuronidate zomepirac. The anti-epileptic drug valproate had no effect on inhibition of thymidine uptake, though, surprisingly, its acyl glucuronide and isomers were active. The reasons for this are unclear at present.
Cannell
G R
GR
Centre for Studies in Drug Disposition, Department of Medicine, The University of Queensland at Royal Brisbane Hospital, Australia.
Vesey
D A
DA
Dickinson
R G
RG
D000215:Acylation; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004008:Diclofenac / Q000378:metabolism / Q000494:pharmacology*; D004061:Diflunisal / Q000378:metabolism / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D020719:Glucuronides / Q000378:metabolism / Q000494:pharmacology*; D019073:HT29 Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D010894:Piroxicam / Q000494:pharmacology; D013237:Stereoisomerism; D013936:Thymidine / Q000378:metabolism; D014046:Tolmetin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D014635:Valproic Acid / Q000378:metabolism / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020719:Glucuronides; D010894:Piroxicam; D004008:Diclofenac; D014635:Valproic Acid; D004061:Diflunisal; C020549:zomepirac; D014046:Tolmetin; D013936:Thymidine